MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis

European Journal of Cancer

Volumn 46, Issue 8, 2010, Pages 1413-1420

  Fargnoli, Maria Concetta ^a   Gandini, Sara ^b   Peris, Ketty ^a   Maisonneuve, Patrick ^b   Raimondi, Sara ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cyclin dependent kinase inhibitor 2A; Familial melanoma; Genetic epidemiology; Melanocortin 1 receptor

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MELANOCORTIN 1 RECEPTOR;

ARTICLE; AUSTRALIA; CANCER DIAGNOSIS; CANCER RISK; EUROPE; FAMILY; GENE INTERACTION; GENE MUTATION; HETEROZYGOTE; HUMAN; MELANOMA; PRIORITY JOURNAL; UNITED STATES; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; MALE; META ANALYSIS; MUTATION; PEDIGREE; RISK; SKIN TUMOR;

AUSTRALIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MELANOMA; MUTATION; ODDS RATIO; PEDIGREE; RECEPTOR, MELANOCORTIN, TYPE 1; SKIN NEOPLASMS; UNITED STATES;

EID: 77951667623     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.01.027     Document Type: Article

References (35)

1. Fargnoli M.C., Argenziano G., Zalaudek I., and Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 6 (2006) 657-670
2. Goldstein A.M., Chan M., Harland M., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66 (2006) 9818-9828
3. Begg C.B., Orlow I., Hummer A.J., et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 97 (2005) 1507-1515
4. Helsing P., Nymoen D.A., Ariansen S., et al. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 47 (2008) 175-184
5. Bishop D.T., Demenais F., Goldstein A.M., et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94 (2002) 894-903
6. Goldstein A.M., Struewing J.P., Chidambaram A., Fraser M.C., and Tucker M.A. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 92 (2000) 1006-1010
7. Chaudru V., Chompret A., Bressac-de Paillerets B., et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 96 (2004) 785-795
8. Raimondi S., Sera F., Gandini S., et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 122 (2008) 2753-2760
9. Sturm R.A. Molecular genetics of human pigmentation diversity. Hum Mol Genet 18 (2009) R9-R17
10. Kennedy C., ter Huurne J., Berkhout M., et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 117 (2001) 294-300
11. Landi M.T., Kanetsky P.A., Tsang S., et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 97 (2005) 998-1007
12. Stratigos A.J., Dimisianos G., Nikolaou V., et al. Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol 126 (2006) 1842-1849
13. Box N.F., Duffy D.L., Chen W., et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69 (2001) 765-773
14. van der Velden P.A., Sandkuijl L.A., Bergman W., et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69 (2001) 774-779
15. Chaudru V., Laud K., Avril M.F., et al. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 14 (2005) 2384-2390
16. Goldstein A.M., Landi M.T., Tsang S., et al. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 14 (2005) 2208-2212
17. Goldstein A.M., Chaudru V., Ghiorzo P., et al. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int J Cancer 121 (2007) 825-831
18. van Houwelingen H.C., Arends L.R., and Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21 (2002) 589-624
19. Greenland S., and Longnecker M. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135 (1992) 1301-1309
20. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
21. Egger M., Davey S.G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
22. Debniak T., Scott R., Masojc B., et al. MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer 119 (2006) 2597-2602
23. Pastorino L., Bonelli L., Ghiorzo P., et al. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell Melanoma Res 21 (2008) 700-709
24. Chaudru V., Lo M.T., Lesueur F., et al. Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes. Fam Cancer 8 (2009) 371-377
25. Council M.L., Gardner J.M., Helms C., et al. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. Exp Dermatol 18 (2009) 485-487
26. Höiom V., Tuominen R., Käller M., et al. MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters. Pigment Cell Melanoma Res 22 (2009) 196-204
27. Peris K., Fargnoli M.C., Pacifico A., et al. CDKN2A and MC1R mutations in patients with sporadic multiple primary melanoma. J Invest Dermatol 122 (2004) 1327-1330
28. Cuéllar F., Puig S., Kolm I., et al. Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers. Br J Dermatol 160 (2009) 48-53
29. Daniotti M., Ferrari A., Frigerio S., et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol 129 (2009) 1759-1768
30. Ghiorzo P., Pastorino L., Pizzichetta M.A., et al. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Res 19 (2009) 142-145
31. Borges A.L., Cuéllar F., Puig-Butillé J.A., et al. CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol 161 (2009) 536-541
32. Peric B., Cerkovnik P., Novakovic S., et al. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families. BMC Med Genet 9 (2008) 86
33. Gerstenblith M.R., Goldstein A.M., Fargnoli M.C., Peris K., and Landi M.T. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 28 (2007) 495-505
34. Pastorino L., Cusano R., Bruno W., et al. Novel MC1R variants in Ligurian melanoma patients and controls. Hum Mutat 2 (2004) 103
35. Yang X.R., Pfeiffer R.M., Wheeler W., et al. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer 125 (2009) 2912-2917